Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of tesnatilimab (JNJ-64304500) in moderately to severely active Crohn's disease
jRCT2080223926Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of NNC0142-0002 in Crohn's disease (7 arms), sponsored by Janssen Pharmaceutical. Started Jun 2018; status: completed.
02
Drugs
NNC0142-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2080223926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223926.